Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472439 | 1.00 | PDE2A (0.49) | PDE2AHTR2AHTR2CHTR2BHRH4 | |
| SCHEMBL10124490 | 0.84 | LMNA (0.38) | PDE2AHTR2AHTR2CHTR2BLMNA | |
| SCHEMBL10304787 | 0.83 | PDE2A (0.52) | PDE2AHTR2AHTR2CHTR2BLMNA | |
| SCHEMBL4550763 | 0.82 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL29685925 | 0.82 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL4233776 | 0.82 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL14120778 | 0.82 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL30557838 | 0.82 | PDE2A (0.66) | PDE2AHTR2AHTR2CHTR2B | |
| SCHEMBL6816690 | 0.82 | PDE2A (0.47) | PDE2AHTR2AHTR2CHTR2BLMNA | |
| SCHEMBL12739064 | 0.82 | POLB (0.40) | PDE2ALMNATP53HTTSCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-03-31 | — | — | US | disclosed |
| CN-113660983-A | Carbamate derivatives and uses thereof | 诺瑟拉有限公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3270926-B1 | TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020152361-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2020-07-30 | — | — | WO | disclosed |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | CASP1, IL1B, PYCARD | PDE2A 900/4885HTR2A 4784/4885HTR2C 4779/4885 |
| US-10358435-B2 | Triazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE4D | PDE2A 1/4885HTR2A 123/4885HTR2C 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.